Annexon Inc
Officers & Directors
William H. Carson, M.D. Director Muneer A. Satter Director Jennifer Lew Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Thomas G. Wiggans Chairperson Bettina M. Cockroft, M.D. Director Jung E. Choi Director William D. Waddill Director Douglas Love, Esq. President and Chief Executive Officer (Principal Executive Officer) We have served as the Company s auditor since. ,
Annexon Inc currently has 96 employees.
News about Annexon Inc Key Personnel |
Overview of Inducement GrantsOn March 17, 2025, Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing innovative therapies for classical complement-mediated neuroinflammatory diseases, announced the approval of an inducement equity grant to a new non-executive employee. This move was made under the terms of the company’s 2022 Employment Inducement Award Plan, following compliance with Nasdaq Listing Rule 5635(c)(4). The grant, approved on March 12, reflects Annexon’s continuing effort to attract skilled professionals as it navigates both clinical development and market challenges.Financial Context and Performance MetricsDespite these strategic hiring initiatives, Annexon s finan...
|
Annexon Expands Senior Leadership to Accelerate Global Neuroinflammatory-Targeted Portfolio
In a move aimed at advancing its late-stage neuroinflammatory-targeted portfolio, Annexon, Inc. has bolstered its senior leadership team. The biopharmaceutical company, known for its novel complement therapies for diseases of the body, brain, and eye, announced the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial; Sunil B. Mehta, Pharm.D as senior vice president of medical affairs; and Myoung Kim, PHD, M.A. M.B.A. as vice president of health economics and outcomes research.
The addition of these seasoned professionals to Annexon s leadership team is expected to bring substan...
|
Annexon Presents Positive Phase 3 Results for ANX005 in Guillain-Barr Syndrome at PNS Annual Meeting
Brisbane, Calif. – At the annual meeting of the Peripheral Nerve Society (PNS) in 2024, Annexon Inc., a clinical-stage biopharmaceutical company focusing on innovative complement medicines for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, shared encouraging findings from the Phase 3 clinical trial of their C1q-targeted immunotherapy, ANX005, in patients with Guillain-Barr Syndrome. The results demonstrated that patients treated with ANX005 experienced faster and more complete recovery from week 1 through week 26, as observed across multiple pre-specified endpoi...
|
|
|
